https://www.celltrionusa.com/press-release/celltrion-usa-receives-us-fda-approval-for-its-oncology-biosimilar-vegzelma-bevacizumab-adcd-for-the-treatment-of-six-types-of-cancer/ 2023-10-05T13:35:33+00:00 https://www.celltrionusa.com/press-release/celltrion-usa-announces-submission-of-the-biologics-license-application-bla-of-novel-subcutaneous-formulation-of-ct-p13-to-us-food-and-drug-administration/ 2023-10-05T13:38:00+00:00 https://www.celltrionusa.com/press-release/celltrion-usa-appoints-thomas-nusbickel-as-chief-commercial-officer/ 2023-10-05T13:39:15+00:00 https://www.celltrionusa.com/press-release/celltrion-usa-announces-us-fda-approval-of-yuflyma-adalimumab-aaty-a-high-concentration-and-citrate-free-formulation-of-humira-adalimumab-biosimilar/ 2023-10-05T13:41:21+00:00 https://www.celltrionusa.com/press-release/celltrion-usa-launches-yuflyma-adalimumab-aaty-a-humira-adalimumab-biosimilar-in-the-united-states/ 2023-10-05T13:42:57+00:00 https://www.celltrionusa.com/press-release/celltrion-usa-has-signed-a-contract-with-ventegra-to-add-yuflyma-adalimumab-aaty-as-a-preferred-formulary-product-in-both-public-and-private-insurance-markets/ 2023-10-06T08:45:35+00:00 https://www.celltrionusa.com/press-release/celltrion-usa-announces-us-fda-approval-of-zymfentra-infliximab-dyyb-the-first-and-only-subcutaneous-infliximab-for-the-treatment-of-people-with-inflammatory-bowel-disease/ 2023-10-23T08:17:55+00:00 https://www.celltrionusa.com/press-release/celltrion-usa-announces-distribution-and-incorporation-of-yuflyma-adalimumab-aaty-a-humira-biosimilar-to-carepartners-specialty-pharmacy-cost-savings-programs/ 2023-10-27T09:12:59+00:00 https://www.celltrionusa.com/press-release/celltrion-usa-completes-submission-of-biologics-license-application-for-ct-p47-a-biosimilar-candidate-of-actemra-tocilizumab/ 2024-03-11T16:59:55+00:00 https://www.celltrionusa.com/press-release/celltrion-completes-submission-of-biologics-license-application-bla-to-us-fda-for-ct-p39-an-interchangeable-biosimilar-candidate-of-xolair-omalizumab/ 2024-03-11T17:00:28+00:00 https://www.celltrionusa.com/press-release/zymfentrainfliximab-dyyb-the-first-and-only-fda-approved-subcutaneous-infliximab-now-commercially-available-in-the-us/ 2024-03-18T10:18:00+00:00 https://www.celltrionusa.com/press-release/celltrion-usas-adalimumab-aaty-biosimilar-to-humira-now-available-at-low-wholesale-acquisition-cost/ 2024-05-10T09:03:28+00:00 https://www.celltrionusa.com/press-release/celltrion-usa-announces-two-year-data-for-zymfentrainfliximab-dyyb-to-be-presented-at-digestive-disease-week-ddw-2024-conference/ 2024-05-17T09:36:59+00:00 https://www.celltrionusa.com/press-release/zymfentra-infliximab-dyyb-demonstrated-long-term-efficacy-and-safety-profile-of-maintenance-treatment-through-two-years-for-adults-with-moderately-to-severely-active-crohns-disease-and-ulcerative-coli/ 2024-05-21T11:21:15+00:00 https://www.celltrionusa.com/press-release/celltrion-usa-announces-incorporation-of-adalimumab-aaty-a-humira-biosimilar-to-the-costco-member-prescription-program/ 2024-08-13T11:22:33+00:00 https://www.celltrionusa.com/press-release/celltrion-presents-post-hoc-analysis-of-liberty-studies-of-zymfentra-infliximab-dyyb-at-the-american-college-of-gastroenterology-2024-annual-scientific-meeting/ 2024-10-30T11:26:29+00:00 https://www.celltrionusa.com/press-release/zymfentra-infliximab-dyyb-coverage-continues-to-increase-through-partnership-with-top-3-pharmacy-benefit-managers-pbms/ 2024-10-31T11:28:40+00:00 https://www.celltrionusa.com/press-release/celltrion-presents-additional-data-from-phase-iii-randomized-controlled-trials-to-further-support-biosimilarity-for-ct-41-biosimilar-candidate-of-denosumab-and-ct-p47-biosimilar-candidate-of-tocilizum/ 2024-11-19T11:32:50+00:00 https://www.celltrionusa.com/press-release/us-fda-approves-celltrions-steqeyma-ustekinumab-stba-a-biosimilar-to-stelara-ustekinumab/ 2024-12-18T11:33:35+00:00 https://www.celltrionusa.com/press-release/us-fda-approves-celltrions-avtozma-tocilizumab-anoh-a-biosimilar-to-actemra/ 2025-01-31T11:37:57+00:00 https://www.celltrionusa.com/press-release/celltrion-receives-us-fda-approval-for-stoboclo-denosumab-bmwo-and-osenvelt-denosumab-bmwo-biosimilars-referencing-prolia-and-xgeva/ 2025-03-04T09:24:00+00:00 https://www.celltrionusa.com/press-release/us-fda-approves-celltrions-omlyclo-omalizumab-igec-as-the-first-and-only-biosimilar-with-interchangeability-designation-referencing-xolair/ 2025-03-10T09:13:39+00:00 https://www.celltrionusa.com/press-release/steqeyma-ustekinumab-stba-a-biosimilar-to-stelara-ustekinumab-now-available-in-the-united-states/ 2025-03-13T10:45:16+00:00 https://www.celltrionusa.com/press-release/celltrions-steqeyma-ustekinumab-stba-now-added-to-the-costco-member-prescription-program/ 2025-03-27T15:05:05+00:00 https://www.celltrionusa.com/press-release/us-fda-grants-interchangeable-designation-to-yuflyma-adalimumab-aaty-celltrions-biosimilar-to-humira-adalimumab/ 2025-04-15T09:55:55+00:00 https://www.celltrionusa.com/press-release/celltrion-to-present-six-abstracts-in-inflammatory-bowel-disease-ibd-at-2025-digestive-disease-week-ddw/ 2025-04-29T09:49:37+00:00 https://www.celltrionusa.com/press-release/celltrions-yuflyma-adalimumab-aaty-receives-fda-interchangeability-designation-for-all-its-approved-dosage-forms-and-strengths/ 2025-05-22T09:29:29+00:00 https://www.celltrionusa.com/press-release/celltrion-usa-announces-appointment-of-dr-juby-jacob-nara-md-as-senior-vice-president-and-chief-medical-officer/ 2025-06-03T00:00:59+00:00 https://www.celltrionusa.com/press-release/celltrion-announces-us-fda-approval-of-additional-presentation-of-steqeyma-ustekinumab-stba-expanding-dosing-options-for-pediatric-patients/ 2025-06-16T09:09:47+00:00 https://www.celltrionusa.com/press-release/celltrion-usa-announces-us-launch-of-denosumab-biosimilars-stoboclo-and-osenvelt-denosumab-bmwo/ 2025-07-08T11:43:23+00:00 https://www.celltrionusa.com/press-release/fda-approves-expanded-indication-for-avtozma-tocilizumab-anoh-intravenous-iv-formulation-in-cytokine-release-syndrome-crs/ 2025-08-07T09:21:30+00:00 https://www.celltrionusa.com/press-release/celltrion-launches-avtozma-tocilizumab-anoh-intravenous-iv-formulation-in-the-united-states/ 2025-10-03T11:14:00+00:00 https://www.celltrionusa.com/press-release/us-fda-grants-interchangeability-designation-to-celltrions-denosumab-biosimilars-stoboclo-denosumab-bmwo-and-osenvelt-denosumab-bmwo/ 2025-10-30T16:53:08+00:00 https://www.celltrionusa.com/press-release/celltrion-announces-publication-of-post-hoc-analysis-of-liberty-cd-study-of-zymfentra-infliximab-dyyb-indicating-consistent-efficacy-across-disease-location-including-the-terminal-ileum-in-clinical-ga/ 2025-11-26T16:54:24+00:00 https://www.celltrionusa.com/press-release/celltrion-announces-us-fda-approval-of-300mg-strength-of-omlyclo-omalizumab-igec-the-first-and-only-fda-approved-interchangeable-biosimilar-to-xolair/ 2025-12-03T10:17:30+00:00 https://www.celltrionusa.com/press-release/celltrion-to-present-at-the-44th-annual-jp-morgan-healthcare-conference/ 2026-01-07T11:10:37+00:00 https://www.celltrionusa.com/press-release/celltrion-presents-innovative-drug-pipeline-and-us-manufacturing-and-rd-expansion-strategy-at-the-44th-annual-jp-morgan-healthcare-conference/ 2026-01-14T11:11:30+00:00 https://www.celltrionusa.com/press-release/celltrion-announces-us-availability-of-avtozma-tocilizumab-anoh-subcutaneous-sc-formulation/ 2026-03-17T13:00:06+00:00 https://www.celltrionusa.com/press-release/celltrion-to-present-seven-abstracts-in-inflammatory-bowel-disease-ibd-at-2026-digestive-disease-week-ddw/ 2026-04-22T13:39:29+00:00 https://www.celltrionusa.com/press-release/celltrion-receives-us-fda-approval-for-eydenzelt-aflibercept-boav-biosimilar-referencing-eylea-aflibercept/ 2026-06-11T19:01:25+00:00 https://www.celltrionusa.com/press-release/fda-approves-expanded-pediatric-indications-for-yuflyma-adalimumab-aaty-and-unbranded-adalimumab-aaty-in-the-united-states-2/ 2026-06-11T19:03:59+00:00